Selective laser trabeculoplasty leads to significant reductions in intraocular pressure in people with primary open-angle glaucoma, a study has found.
Category: News
New Report Calls For Standardised Collection Of Quality Optical Data, UK
The College of Optometrists, the professional, scientific and examining body for optometry in the UK, has published a new report calling for a more efficient collection of good quality data relating to patients’ eye health, in a bid to improve local e…
High Rate Of Vision Problems After Traumatic Brain Injury Found In In Combat Vets And Others
Visual symptoms and abnormalities occur at high rates in people with traumatic brain injury (TBI) – including Iraq and Afghanistan War veterans with blast-related TBI, reports a study, “Abnormal Fixation in Individuals with AMD when Viewing an Image o…
In Mouse Model Of Usher Syndrome, Researchers Develop Rx For Deafness, Impaired Balance
Jennifer Lentz, PhD, Assistant Professor of Otorhinolaryngology & Biocommunications and a member of the Neuroscience Center of Excellence at LSU Health Sciences Center New Orleans, is the lead author of a paper reporting that hearing and balance can be rescued by a new therapy in a mouse model of Usher syndrome (Usher) that contains the mutation responsible for type 1C Usher…
Evidence-Based Guidelines For Automated Preschool Vision Screening
The Vision Screening Committee of the American Association for Pediatric Ophthalmology and Strabismus, the professional organization for pediatric eye care, has revised its guidelines for automated preschool vision screening based on new evidence. The…
Unraveling The Brain’s Vision Secrets
A new study led by scientists at the Universities of York and Bradford has identified the two areas of the brain responsible for our perception of orientation and shape…
Patients Taking Insulin For Type 2 Diabetes May Be At Increased Risk Of Health Complications
Patients with type 2 diabetes treated with insulin could be exposed to a greater risk of health complications including heart attack, stroke, cancer and eye complications a new study has found…
Viral conjunctivitis: potential new treatment
Viral conjunctivitis is a highly contagious infection, often causing major ophthalmic epidemics. There is no approved acute treatment currently approved by the FDA for viral conjunctivitis. A safe broad-spectrum antiviral agent is needed to treat this …
AAPOS committee revises guidelines for automated preschool vision screening
The Vision Screening Committee of the American Association for Pediatric Ophthalmology and Strabismus, the professional organization for pediatric eye care, has revised its guidelines for automated preschool vision screening based on new evidence. The …
Cause of esodeviation differs in children, adults
Children who present with acute-onset esodeviation should be investigated for underlying central nervous system disorders, study findings indicate.
Cataract Surgery in Both Eyes May Boost Benefits
Although one-eye cataract surgery improves vision, including the second eye may yield greater rewards, researchers suggest. Reuters Health Information
LipiView Version 2.0 Software Receives FDA Clearance
The FDA has cleared additional features and broadened
the indication for the use of the LipiView Ocular
Surface Interferometer (TearScience, Inc.), according to
a news release. The device can now measure the absolute
thickness of the tear film lipid la…
Warburg to Hire Goldman Sachs to Sell Bausch + Lomb
Warburg Pincus LLC hired Goldman Sachs Group, Inc.,
to explore the sale of Bausch + Lomb, according to several
news reports.
Warburg may seek at least $10 billion for the business,
according to a Bloomberg News report, which cited two
unnamed sources …
Sulcus-Diameter–Based Formula Achieved Predictable Sizing of Visian ICL
Significantly better predictability of postoperative vault
height was achieved by including a sulcusdiameter–
based formula in the sizing formula for the
Visian Implantable Collamer Lens (ICL; STAAR Surgical)
compared with only using the traditional white-towhite–
based formula, according to a study in the Journal
…
First Patient Treated With Ocriplasmin at Wills Eye Hospital
Allen C. Ho, MD, treated the first patient with ocriplasmin
(Jetrea; ThromboGenics) at the Wills Eye
Hospital in Philadelphia. Dr. Ho is a professor of ophthalmology
at Thomas Jefferson University Retina Service and Wills Eye Hospital and Chief Medical Editor of Advanced Ocular Care’s sister publication Retina Today.
…
Bausch + Lomb Completes Acquisition of Technolas Perfect Vision GmbH
Bausch + Lomb has completed its acquisition of
Technolas Perfect Vision GmbH. The new entity will
be known as Bausch + Lomb Technolas, according to a
company news release. The financial terms of the deal
were not disclosed.
Technolas Perfect Vision will become part of Bausch
+ Lomb’s surgical business, and its fem…
Possible Negative Side Effects of VEGF Inhibition Therapy?
A report in Investigative Ophthalmology and Visual
Science revealed that increasingly aggressive therapies
that block vascular endothelial growth factor (VEGF)
could cause damage in treating eye diseases.1 Scientists
discovered inhibiting anti-VEGF mig…
Alcon and Bausch + Lomb Each Release New Treatment Options for Postoperative Pain and Inflammation
At the Hawaiian Eye meeting in Waikoloa, Hawaii,
Alcon Laboratories, Inc., and Bausch + Lomb separately
announced the US release of treatments for pain and
inflammation following cataract surgery.
Alcon launched Ilevro (nepafenac ophthalmic suspension…
UCSF Teams Tackle Childhood Mortality and River Blindness
Two teams of researchers from the University of
California San Francisco (UCSF) have received more than
$16 million from the Bill and Melinda Gates Foundation to
study new ways to significantly reduce childhood mortality
and disease in developing natio…
InSite Vision Completes Phase 3 Clinical Study of BromSite
The final patient has completed dosing and evaluation
in InSite Vision’s phase 3 clinical trial of BromSite (ISV-
303) for the reduction of pain and inflammation after
cataract surgery. BromSite combines a low dose (0.075%)
of the agent bromfenac with InSite Vision’s DuraSite
drug-delivery technology. Top-line data…